Ductal carcinoma in situ of the breast

BMJ (Online)

Volumn 344, Issue 7846, 2012, Pages

  Barnes, Nicola L P ^a   Ooi, Jane L ^a   Yarnold, John R ^b   Bundred, Nigel J ^c  

^a ROYAL BOLTON HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE; STEROID; TAMOXIFEN;

BREAST BIOPSY; BREAST CALCIFICATION; BREAST CARCINOGENESIS; BREAST HYPERPLASIA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER RISK; CANCER SCREENING; CANCER STEM CELL; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FAMILY HISTORY; GENETIC ASSOCIATION; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTECTOMY; MEDICAL AUDIT; NUCLEAR MAGNETIC RESONANCE IMAGING; PAGET NIPPLE DISEASE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SIGNAL TRANSDUCTION; SOCIAL PSYCHOLOGY; WATCHFUL WAITING; WIDE EXCISION; ADULT; BREAST TUMOR; FEMALE; MIDDLE AGED; RISK FACTOR;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; MIDDLE AGED; RISK FACTORS;

EID: 84857832783     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e797     Document Type: Review

References (34)

1. NHS cancer screening programmes. All breast cancer report. An analysis of all symptomatic and screen detected breast cancers diagnosed in 2006. NHS breast screening programme Oct 2009.
2. NHS Breast Screening Programme. Pathology reporting of breast disease. National Pathology Co-ordinating Group. Publication no 58, 2005.
3. Hwang ES, DeVries S, Chew KL, Moore DH 2nd, Kerlikowske K, Thor A, et al. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res 2004;10:5160-7. (Pubitemid 39099791)
4. Claus EB, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 2001;93:1811-7. (Pubitemid 33150454)
5. Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 2005;293:964-9. (Pubitemid 40271128)
6. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53. (Pubitemid 37430077)
7. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
8. Menes TS, Kerlikowske K, Jaffer S, Seger D, Miglioretti DL. Rates of atypical ductal hyperplasia have declined with less use of postmenopausal hormone treatment: findings from the Breast Cancer Surveillance Consortium. Cancer Epidemiol Biomarkers Prev 2009;18:2822-8.
9. Pappo I, Wasserman I, Halevy A. Ductal carcinoma in situ of the breast in men: a review. Clin Breast Cancer 2005;6:310-4. (Pubitemid 41715691)
10. Brennan ME, Turner RM, Ciatto S, Marinovich ML, French JR, Macaskill P, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 2011;260:119-28.
11. National Institute for Health and Clinical Excellence. Early and locally advanced breast cancer diagnosis and treatment. CG80. 2009. www.nice.org.uk/ CG80.
12. Tang S, Twelves D, Isacke C, Gui G. Mammary ductoscopy in the current management of breast disease. Surg Endosc 2010;25:1712-22.
13. Lehman CD. Magnetic resonance imaging in the evaluation of ductal carcinoma in situ. J Natl Cancer Monogr 2010;2010:150-1.
14. Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: ten-year results of EORTC randomized phase III trial 10853. J Clin Oncol 2006;243:381-7.
15. Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight year update of protocol B17: intraductal carcinoma. Cancer 1999;86:429-38. (Pubitemid 29347405)
16. Cuzick J, Sestaka I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2010;12:21-9.
17. Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, et al. SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 2006;45:536-43. (Pubitemid 44167203)
18. Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev 2009;21:CD000563.
19. Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson JJ, Julien TB, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011;103:478-88.
20. Fisher B, Dignam J, Wolmark N,Wickerman DC, Fisher ER, Mamounas EP, et al. Tamoxifen in the treatment of intraductal breast cancer: national surgical adjuvant breast and bowel project B-24 randomised controlled trial. Lancet 1999;353:1993-2000. (Pubitemid 29271743)
21. Allred DC, Bryant J, Land S, Paik S, Fisher E, Julien T, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of intraductal breast cancer: findings of the NSABP protocol B-24 [abstract]. Breast Cancer Res Treat 2002;76(suppl 1):S36.
22. Barnes NL, Boland GP, Davenport A, Knox WF, Bundred NJ. Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ. Br J Surg 2005;92:429-34. (Pubitemid 40523904)
23. Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactanski-Wende J, et al NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91.
24. Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ. Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat 2011;129:165-73.
25. Graff S. Ductal carcinoma in situ: should the name be changed? J Natl Cancer Inst 2010;102:6-8.
26. Chen YY, DeVries S, Anderson J, Lessing J, Swain R, Cin K, et al. Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer 2009;9:285.
27. Julien J, Bijker N, Fentiman I, Peterse JL, Delledonne V, Rouanet P, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomized phase III trial 10853. Lancet 2000;355:528-33. (Pubitemid 30088672)
28. Bijker N, Peterse JL, Duchateaul, Julien JP, Fentiman IS, Duval C, et al. Risk factors for recurrence and metastasis after breast conserving therapy for ductal carcinoma in situ: analysis of EORTC trial. J Clin Oncol 2001;19:2263-71. (Pubitemid 32366979)
29. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003;362:95-102. (Pubitemid 36831018)
30. Silverstein MJ, Lagios MD. Choosing treatment for patients with DCIS: fine tuning the University of Southern California/Van-Nuys prognostic index. J Natl Cancer Inst Monogr 2010;41:193-6.
31. Boland GP, Chan KC, Knox WF, Roberts SA, Bundred NJ. Value of the Van Nuys prognostic index in prediction of recurrence o ductal carcinoma in situ after breast-conserving surgery. Br J Surg 2003;90:426-32. (Pubitemid 36458104)
32. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 2010;70:709-18.
33. Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, et al. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 2008;100:243-51. (Pubitemid 351480537)
34. Kennedy F, Harcourt D, Rumsey N, White P. The psychosocial impact of ductal carcinoma in situ (DCIS): a longitudinal prospective study. Breast 2010;19:382-7.